Unknown

Dataset Information

0

Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Cote d'Ivoire.


ABSTRACT: OBJECTIVE:In sub-Saharan Africa, HIV-infected adults who fail second-line antiretroviral therapy (ART) often do not have access to third-line ART. We examined the clinical impact and cost-effectiveness of making third-line ART available in Côte d'Ivoire. METHODS:We used a simulation model to compare 4 strategies after second-line ART failure: continue second-line ART (C-ART2), continue second-line ART with an adherence reinforcement intervention (AR-ART2), immediate switch to third-line ART (IS-ART3), and continue second-line ART with adherence reinforcement, switching patients with persistent failure to third-line ART (AR-ART3). Third-line ART consisted of a boosted-darunavir plus raltegravir-based regimen. Primary outcomes were 10-year survival and lifetime incremental cost-effectiveness ratios (ICERs), in $/year of life saved (YLS). ICERs below $3585 (3 times the country per capita gross domestic product) were considered cost-effective. RESULTS:Ten-year survival was 6.0% with C-ART2, 17.0% with AR-ART2, 35.4% with IS-ART3, and 37.2% with AR-ART3. AR-ART2 was cost-effective ($1100/YLS). AR-ART3 had an ICER of $3600/YLS and became cost-effective if the cost of third-line ART decreased by <1%. IS-ART3 was less effective and more costly than AR-ART3. Results were robust to wide variations in the efficacy of third-line ART and of the adherence reinforcement, as well as in the cost of second-line ART. CONCLUSIONS:Access to third-line ART combined with an intense adherence reinforcement phase, used as a tool to distinguish between patients who can still benefit from their current second-line regimen and those who truly need third-line ART would provide substantial survival benefits. With minor decreases in drug costs, this strategy would be cost-effective.

SUBMITTER: Ouattara EN 

PROVIDER: S-EPMC4146647 | biostudies-literature | 2014 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinical impact and cost-effectiveness of making third-line antiretroviral therapy available in sub-Saharan Africa: a model-based analysis in Côte d'Ivoire.

Ouattara Eric N EN   Ross Eric L EL   Yazdanpanah Yazdan Y   Wong Angela Y AY   Robine Marion M   Losina Elena E   Moh Raoul R   Walensky Rochelle P RP   Danel Christine C   Paltiel A David AD   Eholié Serge P SP   Freedberg Kenneth A KA   Anglaret Xavier X  

Journal of acquired immune deficiency syndromes (1999) 20140701 3


<h4>Objective</h4>In sub-Saharan Africa, HIV-infected adults who fail second-line antiretroviral therapy (ART) often do not have access to third-line ART. We examined the clinical impact and cost-effectiveness of making third-line ART available in Côte d'Ivoire.<h4>Methods</h4>We used a simulation model to compare 4 strategies after second-line ART failure: continue second-line ART (C-ART2), continue second-line ART with an adherence reinforcement intervention (AR-ART2), immediate switch to thir  ...[more]

Similar Datasets

| S-EPMC6479434 | biostudies-literature
| S-EPMC8323268 | biostudies-literature
| S-EPMC7406077 | biostudies-literature
| S-EPMC6597104 | biostudies-literature
| S-EPMC6884078 | biostudies-literature
| S-EPMC6746366 | biostudies-literature
| S-EPMC6332523 | biostudies-literature
| S-EPMC7861518 | biostudies-literature
| S-EPMC4500741 | biostudies-literature
| S-EPMC4898722 | biostudies-literature